Market Cap 18.77B
Revenue (ttm) 14.30B
Net Income (ttm) -3.51B
EPS (ttm) N/A
PE Ratio 6.70
Forward PE 6.78
Profit Margin -24.58%
Debt to Equity Ratio 0.94
Volume 12,669,700
Avg Vol 9,750,970
Day's Range N/A - N/A
Shares Out 1.15B
Stochastic %K 47%
Beta 0.90
Analysts Sell
Price Target $18.89

Company Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 724 514 1800
Address:
Robert J. Coury Global Center, 1000 Mylan Boulevard, Canonsburg, United States
macrossluvsrobotech
macrossluvsrobotech Aug. 31 at 2:22 PM
$LXRX 🚨 New ESC 2026 & JACC Data: Addressing the "Recycled Data" FUD on SOLOIST-WHF. Skeptics claim today's PR is just rehashed data. Let's look at the facts: WHAT’S NEW: A newly published subgroup analysis evaluating Sotagliflozin (INPEFA) across baseline Systolic Blood Pressure (SBP) levels: • SBP <110 mmHg (n=201): HR 0.56 (p=0.03) — 44% reduction in CV death & HF events! • SBP ≥110 mmHg: HR 0.69 (p=0.01). • Safety: NO increased risk of hypotension (p=0.34) or acute kidney injury (p=0.69) vs placebo, even down to 100 mmHg baseline SBP. WHY IT MATTERS: In the real world, cardiologists hesitate to prescribe SGLT inhibitors to low-BP, fragile heart failure patients fearing dangerous blood pressure drops or kidney strain. This gives physicians peer-reviewed proof in JACC: Heart Failure that INPEFA is safe and effective in this vulnerable cohort. It directly dismantles a major prescribing hurdle. Solid clinical execution! 📈 PR: https://lexiconpharma.gcs-web.com/news-releases/news-release-details/lexicon-announces-new-post-hoc-soloist-whf-analysis $NVO $VTRS $BIB $LLY
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 28 at 6:40 PM
$LXRX Into Midterms ( Exton and Debbane are playing this perfectly ) Trump admin will want to take credit for being the first ever Administration to provide an oral supplement to ease or greatly reduce, perhaps replace for many, the use of a painful injection, jab of insulin. Watch. Type 1 Diabetes. Gonna Make Type 1 Diabetes Management... Great .....Again. $NVO $VTRS $BIB $LLY
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 26 at 10:11 PM
$LXRX Trump will want his admin to take credit for... drum roll..... Midterms will make sure the US citizen get's an alternative to a painful Insulin Jab, = an oral pill, first one ever. ; ) To control glycemic index. You think he gets more votes that way? I do. $VTRS $NVO $BIB
1 · Reply
SuperGreenToday
SuperGreenToday Aug. 26 at 8:51 PM
$VTRS Share Price: $16.86 Contract Selected: Apr 16, 2027 $19.0 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.71 – $0.87 Potential Upside: 75% ROI Time to Expiration: 232 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 25 at 11:39 PM
$LXRX 🚨 Huge Catalyst Update! Lexicon just banked another $10M from $NVO Novo Nordisk for the LX9851 Phase 1 dosing milestone. Here is what we can deduce & why this is massively bullish: 💰 Non-Dilutive Cash: This is the third $10M payment in 2026. LXRX has now secured $75M out of the potential $1B. This non-dilutive capital strengthens the balance sheet and reduces financing risks. 🔬 Clinical Progress: Hitting dosing milestones confirms the Phase 1 trial is advancing smoothly without major safety setbacks. Novo is executing aggressively, with Phase 1 completion slated for Q1 2027. LX9851 (ACSL5 inhibitor) is proving to be a priority for Novo's post-GLP-1 obesity pipeline. 🔥 The Double Catalyst: This clinical momentum perfectly aligns with the upcoming sotagliflozin (Inpefa) resubmission for Type 1 Diabetes. Having a partner like Novo executing flawlessly on LX9851 de-risks the broader pipeline while we wait for the FDA. The setup here is incredibly asymmetric! 📈👀 $NVO $VTRS $BIB
0 · Reply
BuyHighSellLowGER
BuyHighSellLowGER Aug. 20 at 8:02 PM
$VTRS PoS. Too greedy again. Wanted 20$ and was stupid enough not to sell at 18$. Same like $SBUX that is primed to go back to 95$ next week. Ugly days to come. At least selling $SWK above 100$ recently was not too bad.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 13 at 6:11 PM
$LXRX $NVO $VTRS Dr Edelman is total proponent of Zynquista for T1 - A towering authority in his field, that completely has our back = $LXRX
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 13 at 5:19 PM
$LXRX watch: Lexicon is exhibiting at TCOYD [Taking Control Of Your Diabetes] ONE 2026, Aug 14-16, San Diego. TCOYD is led by Dr. Steve Edelman (Founder/Director, UCSD Prof. of Medicine) and Dr. Jeremy Pettus (UCSD Assoc. Prof.) — independent physicians, not Lexicon staff, but longtime T1D [type 1 diabetes] advocates for options beyond insulin. Fresh catalyst: on Lexicon's Q2 2026 call, mgmt said STENO1 (Steno Diabetes Center, Denmark) is nearing the exposure threshold FDA flagged as sufficient for NDA [New Drug Application] resubmission of Zynquista (sotagliflozin) in T1D. Exposure expected by end of Aug 2026; DKA [diabetic ketoacidosis] rates similar to standard-of-care, below earlier trials. Resubmission targeted Q4 2026. Watching conference + STENO1 data into Q4. NFA. DYOR. https://www.linkedin.com/posts/lexicon-pharmaceuticals_lexicon-t1d-dpnp-activity-7493668586708885504-LpTh?utm_source=share&utm_medium=member_ios&rcm=ACoAAAsxtNMB_-3m9veO28z6qXYyCblWycfZlRA $VTRS $NVO
0 · Reply
dllydalley29
dllydalley29 Aug. 11 at 9:15 PM
$VTRS Picking up a few more here on weakness.
2 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 7 at 2:41 PM
$LXRX Canada, Australia = Inpefa... and many more to come. $VTRS hustling.
0 · Reply
Latest News on VTRS
Viatris Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 25 days ago

Viatris Earnings Call Transcript: Q2 2026


Viatris Slides: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 25 days ago

Viatris Slides: Q2 2026


Viatris Earnings release: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 25 days ago

Viatris Earnings release: Q2 2026


Viatris Quarterly report: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 25 days ago

Viatris Quarterly report: Q2 2026


Viatris reports Q2 adjusted EPS 69c, consensus 60c

2026-08-06T11:12:48.000Z - 25 days ago

Viatris reports Q2 adjusted EPS 69c, consensus 60c


Viatris Reports Second-Quarter 2026 Financial Results

Aug 6, 2026, 6:59 AM EDT - 25 days ago

Viatris Reports Second-Quarter 2026 Financial Results


Viatris Announces Quarterly Dividend

Aug 4, 2026, 6:59 AM EDT - 27 days ago

Viatris Announces Quarterly Dividend


Viatris receives FDA approval for Gwyn Lo contraceptive patch

2026-07-29T13:16:04.000Z - 4 weeks ago

Viatris receives FDA approval for Gwyn Lo contraceptive patch


Viatris announces VR-205 trial achieves primary endpoint

2026-06-29T11:05:13.000Z - 2 months ago

Viatris announces VR-205 trial achieves primary endpoint


Viatris price target raised to $22 from $17 at Barclays

2026-05-19T09:20:10.000Z - 3 months ago

Viatris price target raised to $22 from $17 at Barclays


Viatris says FDA accepts for review NDA for MR-107A-02

2026-05-18T12:09:01.000Z - 3 months ago

Viatris says FDA accepts for review NDA for MR-107A-02


Viatris price target raised to $20 from $18 at Truist

2026-05-08T14:11:09.000Z - 4 months ago

Viatris price target raised to $20 from $18 at Truist


Viatris price target raised to $18 from $17 at JPMorgan

2026-05-08T12:28:39.000Z - 4 months ago

Viatris price target raised to $18 from $17 at JPMorgan


Viatris reports Q1 adjusted EPS 59c, consensus 50c

2026-05-07T16:28:39.000Z - 4 months ago

Viatris reports Q1 adjusted EPS 59c, consensus 50c


Viatris Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

Viatris Earnings Call Transcript: Q1 2026


Viatris Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

Viatris Slides: Q1 2026


Viatris Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

Viatris Earnings release: Q1 2026


Viatris Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

Viatris Quarterly report: Q1 2026


Viatris Reports First-Quarter 2026 Financial Results

May 7, 2026, 6:59 AM EDT - 4 months ago

Viatris Reports First-Quarter 2026 Financial Results


Viatris Announces Chief Financial Officer Transition

May 4, 2026, 4:30 PM EDT - 4 months ago

Viatris Announces Chief Financial Officer Transition


Viatris Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Viatris Proxy statement: Proxy filing


Viatris Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Viatris Proxy statement: Proxy filing


Viatris price target raised to $17 from $15 at Barclays

2026-03-24T09:41:03.000Z - 5 months ago

Viatris price target raised to $17 from $15 at Barclays


Viatris Transcript: Investor update

Mar 19, 2026, 10:00 AM EDT - 5 months ago

Viatris Transcript: Investor update


Viatris Press release: Investor update

Mar 19, 2026, 10:00 AM EDT - 5 months ago

Viatris Press release: Investor update


Viatris Slides: Investor update

Mar 19, 2026, 10:00 AM EDT - 5 months ago

Viatris Slides: Investor update


Viatris outlines vision for growth through 2030

2026-03-19T13:15:32.000Z - 5 months ago

Viatris outlines vision for growth through 2030


Viatris Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Viatris Earnings Call Transcript: Q4 2025


Viatris Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Viatris Annual report: Q4 2025


Viatris Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Viatris Earnings release: Q4 2025


Viatris Slides: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Viatris Slides: Q4 2025


Viatris Appoints Matthew J. Maletta as Chief Legal Officer

Feb 3, 2026, 8:30 AM EST - 7 months ago

Viatris Appoints Matthew J. Maletta as Chief Legal Officer


Viatris Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 12:00 PM EST - 8 months ago

Viatris Transcript: 44th Annual J.P. Morgan Healthcare Conference


Viatris Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 12:00 PM EST - 8 months ago

Viatris Slides: 44th Annual J.P. Morgan Healthcare Conference


Viatris Provides Pipeline Update on Four Regulatory Milestones

Dec 18, 2025, 6:59 AM EST - 9 months ago

Viatris Provides Pipeline Update on Four Regulatory Milestones


Viatris to Participate in Upcoming Investor Conferences

Nov 24, 2025, 8:00 AM EST - 10 months ago

Viatris to Participate in Upcoming Investor Conferences


Viatris Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 6:30 AM EST - 10 months ago

Viatris Transcript: Jefferies London Healthcare Conference 2025


Viatris Transcript: UBS Global Healthcare Conference 2025

Nov 11, 2025, 8:45 AM EST - 10 months ago

Viatris Transcript: UBS Global Healthcare Conference 2025


Viatris Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Viatris Earnings Call Transcript: Q3 2025


Viatris Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Viatris Quarterly report: Q3 2025


Viatris Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Viatris Earnings release: Q3 2025


Viatris Slides: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Viatris Slides: Q3 2025


Viatris Proxy statement: Proxy Filing

Oct 24, 2025, 8:00 AM EDT - 11 months ago

Viatris Proxy statement: Proxy Filing


Viatris Proxy statement: Proxy Filing

Oct 24, 2025, 8:00 AM EDT - 11 months ago

Viatris Proxy statement: Proxy Filing


Viatris Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Viatris Earnings Call Transcript: Q2 2025


Viatris Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Viatris Quarterly report: Q2 2025


Viatris Earnings release: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Viatris Earnings release: Q2 2025


Viatris Slides: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Viatris Slides: Q2 2025


Viatris eye therapy fails to meet late-stage trial goal

Jul 18, 2025, 7:07 AM EDT - 1 year ago

Viatris eye therapy fails to meet late-stage trial goal


macrossluvsrobotech
macrossluvsrobotech Aug. 31 at 2:22 PM
$LXRX 🚨 New ESC 2026 & JACC Data: Addressing the "Recycled Data" FUD on SOLOIST-WHF. Skeptics claim today's PR is just rehashed data. Let's look at the facts: WHAT’S NEW: A newly published subgroup analysis evaluating Sotagliflozin (INPEFA) across baseline Systolic Blood Pressure (SBP) levels: • SBP <110 mmHg (n=201): HR 0.56 (p=0.03) — 44% reduction in CV death & HF events! • SBP ≥110 mmHg: HR 0.69 (p=0.01). • Safety: NO increased risk of hypotension (p=0.34) or acute kidney injury (p=0.69) vs placebo, even down to 100 mmHg baseline SBP. WHY IT MATTERS: In the real world, cardiologists hesitate to prescribe SGLT inhibitors to low-BP, fragile heart failure patients fearing dangerous blood pressure drops or kidney strain. This gives physicians peer-reviewed proof in JACC: Heart Failure that INPEFA is safe and effective in this vulnerable cohort. It directly dismantles a major prescribing hurdle. Solid clinical execution! 📈 PR: https://lexiconpharma.gcs-web.com/news-releases/news-release-details/lexicon-announces-new-post-hoc-soloist-whf-analysis $NVO $VTRS $BIB $LLY
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 28 at 6:40 PM
$LXRX Into Midterms ( Exton and Debbane are playing this perfectly ) Trump admin will want to take credit for being the first ever Administration to provide an oral supplement to ease or greatly reduce, perhaps replace for many, the use of a painful injection, jab of insulin. Watch. Type 1 Diabetes. Gonna Make Type 1 Diabetes Management... Great .....Again. $NVO $VTRS $BIB $LLY
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 26 at 10:11 PM
$LXRX Trump will want his admin to take credit for... drum roll..... Midterms will make sure the US citizen get's an alternative to a painful Insulin Jab, = an oral pill, first one ever. ; ) To control glycemic index. You think he gets more votes that way? I do. $VTRS $NVO $BIB
1 · Reply
SuperGreenToday
SuperGreenToday Aug. 26 at 8:51 PM
$VTRS Share Price: $16.86 Contract Selected: Apr 16, 2027 $19.0 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.71 – $0.87 Potential Upside: 75% ROI Time to Expiration: 232 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 25 at 11:39 PM
$LXRX 🚨 Huge Catalyst Update! Lexicon just banked another $10M from $NVO Novo Nordisk for the LX9851 Phase 1 dosing milestone. Here is what we can deduce & why this is massively bullish: 💰 Non-Dilutive Cash: This is the third $10M payment in 2026. LXRX has now secured $75M out of the potential $1B. This non-dilutive capital strengthens the balance sheet and reduces financing risks. 🔬 Clinical Progress: Hitting dosing milestones confirms the Phase 1 trial is advancing smoothly without major safety setbacks. Novo is executing aggressively, with Phase 1 completion slated for Q1 2027. LX9851 (ACSL5 inhibitor) is proving to be a priority for Novo's post-GLP-1 obesity pipeline. 🔥 The Double Catalyst: This clinical momentum perfectly aligns with the upcoming sotagliflozin (Inpefa) resubmission for Type 1 Diabetes. Having a partner like Novo executing flawlessly on LX9851 de-risks the broader pipeline while we wait for the FDA. The setup here is incredibly asymmetric! 📈👀 $NVO $VTRS $BIB
0 · Reply
BuyHighSellLowGER
BuyHighSellLowGER Aug. 20 at 8:02 PM
$VTRS PoS. Too greedy again. Wanted 20$ and was stupid enough not to sell at 18$. Same like $SBUX that is primed to go back to 95$ next week. Ugly days to come. At least selling $SWK above 100$ recently was not too bad.
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 13 at 6:11 PM
$LXRX $NVO $VTRS Dr Edelman is total proponent of Zynquista for T1 - A towering authority in his field, that completely has our back = $LXRX
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 13 at 5:19 PM
$LXRX watch: Lexicon is exhibiting at TCOYD [Taking Control Of Your Diabetes] ONE 2026, Aug 14-16, San Diego. TCOYD is led by Dr. Steve Edelman (Founder/Director, UCSD Prof. of Medicine) and Dr. Jeremy Pettus (UCSD Assoc. Prof.) — independent physicians, not Lexicon staff, but longtime T1D [type 1 diabetes] advocates for options beyond insulin. Fresh catalyst: on Lexicon's Q2 2026 call, mgmt said STENO1 (Steno Diabetes Center, Denmark) is nearing the exposure threshold FDA flagged as sufficient for NDA [New Drug Application] resubmission of Zynquista (sotagliflozin) in T1D. Exposure expected by end of Aug 2026; DKA [diabetic ketoacidosis] rates similar to standard-of-care, below earlier trials. Resubmission targeted Q4 2026. Watching conference + STENO1 data into Q4. NFA. DYOR. https://www.linkedin.com/posts/lexicon-pharmaceuticals_lexicon-t1d-dpnp-activity-7493668586708885504-LpTh?utm_source=share&utm_medium=member_ios&rcm=ACoAAAsxtNMB_-3m9veO28z6qXYyCblWycfZlRA $VTRS $NVO
0 · Reply
dllydalley29
dllydalley29 Aug. 11 at 9:15 PM
$VTRS Picking up a few more here on weakness.
2 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 7 at 2:41 PM
$LXRX Canada, Australia = Inpefa... and many more to come. $VTRS hustling.
0 · Reply
MarketPulsee
MarketPulsee Aug. 6 at 10:28 PM
Stocks hitting new 52-week highs today: $BRK.B $RTX $BAC $GE $VTRS A broad group of sectors are showing strength: Financials Industrials Healthcare Aerospace Energy Consumer When multiple sectors are making new highs, it can signal broader market participation beyond just a handful of mega-cap names. The key is identifying which companies have the fundamentals and growth catalysts to continue the trend. Follow my profile for more market trends, stock ideas, and investment insights. NFA. DYOR.
0 · Reply
FibonacciTrader_
FibonacciTrader_ Aug. 6 at 9:39 PM
Fresh 52-Week Highs Alert! These names all reached new 52-week highs during today’s session: $BRK.B $RTX $BAC $GE $VTRS Strong momentum, improving sentiment, and buyers stepping in across multiple sectors. Which one is still just getting started? Next alert is coming soon. If you’re not following with notifications on, you’re likely seeing the move after it already happened
0 · Reply
ItsCarRamRod
ItsCarRamRod Aug. 6 at 7:47 PM
$VTRS VTRS today.
1 · Reply
ItsCarRamRod
ItsCarRamRod Aug. 6 at 7:37 PM
$VTRS WOW, over -$1 down on ER report.
1 · Reply
dllydalley29
dllydalley29 Aug. 6 at 6:38 PM
$VTRS Bought a little on today's weakness.
0 · Reply
RouterReturns
RouterReturns Aug. 6 at 5:01 PM
$VTRS For a company in the peptide and stem cell space RMTG is executing at a level that is rare they have revenue they have growth and they have profits BSEM is still in the development stage financially with huge losses every quarter the difference in maturity between the two companies is striking.
0 · Reply
EarningsInsider
EarningsInsider Aug. 6 at 2:02 PM
https://www.marketbeat.com/earnings/reports/2026-8-6-viatris-inc-stock/ $VTRS Viatris Earnings Transcript
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Aug. 6 at 1:30 PM
$LXRX $VTRS = our ONLY access to sales is just getting started with roll out... Street had this too high, to save some shorts and give a few whales nice entries. Before what really matters = TYPE 1 Diabetes resubmission.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 6 at 12:02 PM
$VTRS Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.10 • Reported revenue of $3.76B up 4.88% YoY • Viatris Inc. raised its 2026 financial guidance midpoints, now expecting total revenues of $14,550 million to $14,950 million, adjusted EBITDA of $4,300 million to $4,500 million, and adjusted EPS of $2.45 to $2.59.
0 · Reply
Estimize
Estimize Aug. 4 at 1:15 PM
Wall St is expecting 0.60 EPS for $VTRS Q2 [Reporting 08/06 BMO] http://www.estimize.com/intro/vtrs?chart=historical&metric_name=eps&utm_co
0 · Reply
clan
clan Aug. 2 at 1:26 PM
$ELTP 10-K for Elite Pharma. "Recent Developments: On April 2, 2026, we announced the comercial launch of our generic methadone hydrochloride 5 mg and 10 mg tablets. 💊 The product is marketed and sold under the Elite Labs label and represents an expansion of the Elite Pharmaceuticals' generic product portfolio. On June 1, 2026, Elite filed an Abbreviated New Drug Application [ANDA] with the US Food and Drug Administration for a generic version of an undisclosed 🤔 drug product in the class of medications caled anticoagulants."[Eloquis] 😲 $TEVA $JNJ 😲 $VTRS
0 · Reply
roblake29
roblake29 Jul. 31 at 9:31 PM
$VTRS My latest. A sell rating on @ViatrisInc Overvalued, overleveraged, and investors seem not to have priced in the obvious risks. Naturally, I'm expecting some pushback: https://seekingalpha.com/article/4928933-low-growth-viatris-is-due-for-a-pullback-after-a-stellar-16-month-run
1 · Reply